Tag: MSc

Poster-Disease-modifying Therapy

Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit

Background: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of...

Read More

Poster-Disease-modifying Therapy

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More

Poster-Disease-modifying Therapy

Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Platform-Rehabilitation

Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.

Background: People with moderate-to-severe multiple sclerosis (MS) and their family caregivers do not engage in sufficient physical...

Read More

Platform-Disease Modifying Therapies

Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...

Read More